Raymond James Financial Services Advisors, Inc. Myriad Genetics Inc Transaction History

Raymond James Financial Services Advisors, Inc.

$73.5 Billion
Q3 2024

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2019 Aug 06, 2019	SELL	$22.67 - $35.0 $200,538 - $309,610	-8,846 Closed	0 $0
Q1 2019 May 06, 2019	BUY	$26.93 - $34.7 $238,222 - $306,956	8,846 New	8,846 $294,000
Q4 2018 Feb 11, 2019	SELL	$27.23 - $45.56 $121,391 - $203,106	-4,458 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$37.57 - $50.34 $167,487 - $224,415	4,458 New	4,458 $205,000

Others Institutions Holding MYGN

# of Institutions

254

Shares Held

90.9M

Call Options Held

100K

Put Options Held

34K

Black Rock Inc. New York, NY

15.2M
Shares

$220 Million
0.01% of portfolio
Vanguard Group Inc Valley Forge, PA

10.3M
Shares

$150 Million
0.01% of portfolio
Wellington Management Group LLP Boston, MA

6.72M
Shares

$97.5 Million
0.03% of portfolio
Israel Englander Millennium Management LLC | New York, Ny

5.18M
Shares

$75.1 Million
0.07% of portfolio
State Street Corp Boston, MA

4.7M
Shares

$68.2 Million
0.01% of portfolio

View Full List

About MYRIAD GENETICS INC

Ticker MYGN
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 80,634,800
Market Cap $1.17B
Description
Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing ...

More about MYGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James Financial Services Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Raymond James Financial Services Advisors, Inc. with notifications on news.

Account